論文

2009年以降に当研究室より発表された論文をご紹介いたします。

2014年

  1. Takeuchi T, Kawai S, Yamamoto K, Harigai M, Ishida K, and Miyasaka M. Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3267 Japanese patients with rheumatoid arthritis. Mod Rheum. 24(1):pp.8-16, 2014.
  2. Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T, Uchida S, Akama H, Hartmut K, Vipin A, and Tanaka Y. Adalimumab, a Human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early RA; the HOPEFUL 1 study. Ann Rheum Dis. 73(3):pp.536-543, 2014.
  3. Nishina N, Kikuchi J, Hashizume M, Yoshimoto K, Kameda H, and Takeuchi T. Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy. Ann Rheum Dis. 73(5):pp.945-7, 2014.
  4. Kaneko Y, Hanaoka H, Hirakata M, Takeuchi T, and Kuwana M. Distinct arthropaties of the hands in patients with anti-aminoacyl tRNA synthetase antibodies: usefulness of autoantibody profiles in classifying patients. Rheumatology. 53(6):pp.1120-24, 2014.
  5. Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M, Iwamoto M, Kohsaka H, Kondo M, Matsubara T, Mimura T, Miyahara H, Ohta S, Saeki Y, Saito K, Sano H, Takasugi K, Takeuchi T, Tohma S, Tsuru T, Ueki Y, Yamana J, Hashimoto J, Matsutani T, Murakami M, Takagi N. Drug free REmission/low disease activity after cessasion of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheum. 24(1):pp.17-25, 2014.
  6. Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M, Iwamoto M, Kohsaka H, Kondo M, Matsubara T, Mimura T, Miyahara H, Ohta S, Saeki Y, Saito K, Sano H, Takasugi K, Takeuchi T, Tohma S, Tsuru T, Ueki Y, Yamana J, Hashimoto J, Matsutani T, Murakami M, Takagi N. Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study. Mod Rheum. 24(1):pp.26-32, 2014.
  7. Kaneko Y, Kuwana M, and Takeuchi T. Osteolytic change in distal interphalangeal joint and sacroiliac joints in subluxing arthropathy in anti-jo-1 antibody. Joint Bone & Spine. 80(5):pp.544-5, 2014.
  8. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Takei S, Tanaka Y, Sano Y, Yamaguchi H, and Yamanaka H. Characteristics related to good effectiveness and safety with tocilizumab: Post-marketing surveillance of 7901 rheumatoid arthritis patients in Japan. J Rheumatology. 41(1):pp.15-23, 2014.
  9. Nishimoto T, Seta N, Anan R, Yamamoto T, Kaneko Y, Takeuchi T, and kuwana M. A single nucleotide polymorphism of TRAF1 predicts the clinical response to anti-TNF treatment in Japanese patients with rheumatoid arthritis. Clin Exp Rheum. 32(2):pp.211-7, 2014.
  10. Kurasawa T, Nagasawa H, Kishimoto M, Amano K, Takeuchi T, and Kameda H. Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: An open, randomized, controlled trial. Mod Rheum. 24(4):pp.561-6, 2014.
  11. Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Shoji T, Sakamaki Y, van der Heijde D, Miyasaka N, and Koike T. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. Mod Rheum. 24(5):pp.715-24, 2014.
  12. Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Iwai K, Sakamaki Y, van der Heijde D, Miyasaka N, and Koike T. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial. Mod Rheum. 24(4):pp.552-60, 2014.
  13. Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N, and Koike T. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study. Mod Rheum. 24(5):pp.725-33, 2014.
  14. Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N, and Koike T. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study. Mod Rheum. 24(5):pp.734-43, 2014.
  15. Tanaka Y, Kubo S, Yamanaka H, Amano K, Hirata S, Tanaka E, Nagasawa H, Yasuoka H, and Takeuchi T. Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia as Biological Intensive Treatment for RA (ORBIT) study. Mod Rheum. 24(5):pp.754-62, 2014.
  16. Yamanaka H, Ishiguro N, Takeuchi, T, Miyasaka N, Mukai M, Matsubara T, Uchida S, Akama H, Kupper H, Arora V, and Tanaka Y. Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial. Rheumatology. 53(5):pp.904-13, 2014.
  17. Iwahashi M, Inoue H, Matsubara T, Tanaka T, Amano K, Kanamono T, Nakano T, Uchimura S, Izumihara T, Yamazaki A, Karyekar C, and Takeuchi T. Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a phase II/III, randomized study. Mod Rheum. 24(6):pp.885-91, 2014.
  18. Mok CC, Yap DY, Navarra SV, Liu Z-H, Zao M-H, Lu L, Takeuchi T, Avihingsanon Y, Yu X-Q, Lapid EA, Lugue-Lizardo LR, Smethkul V, Shen N, Chen S-L, and Chan TM, for the Asian Lupus Nephritis Network. Overview of lupus nephritis management guidelines and perspective from Asia. Nephrology. 19(1):pp.11-20, 2014.
  19. Kaneko Y, Kuwana M, Kondo H, and Takeuchi T. Discordance in global assessments between patient and estimator in patients with newly diagnosed rheumatoid arthritis: associations with progressive joint destruction and functional impairment. J Rheumatology. 41(6):pp.1061-66, 2014.
  20. Takeuchi T, Matsubara T, Urata Y, Suematsu E, Ohta S, Honjyo S, Abe T, Yamamoto A, Miyasaka N, and the Japan Abatacept Study Group. Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate conventional or biologic disease-modifying anti-rheumatic drugs. Mod Rheum. 24(5):pp.744-753, 2014.
  21. Takeuchi T, Matsubara T, Ohta S, Mukai M, Amano K, Tohma S, Tanaka Y, Namanaka H, and Miyasaka N. Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective multi-center, observational study in Japan. Rheumatology. 54(4):pp.683-91, 2015.
  22. Inaba T, Hisatsune C, Sasaki Y, Sasaki Y, Ogawa Y, Ebisu E, Ogawa N, Matsui M, Takeuchi T, Mikoshiba K, and Tsubota T. Mice lacking inositol 1,4,5-triphospate receptors exhibit dry eye. Plos One. 9(6):e99205, 2014.
  23. Kaneko Y, Koike T, Oda H, Yamamoto K, Miyasaka N, Harigai M, Yamanaka H, Ishiguro N, Tanaka Y, and Takeuchi T. Obstacles to the implementation of the treat-to-target strategy for rheumatoid arthritis in clinical practice in Japan. Mod Rheum. 25(1):pp.43-9, 2015.
  24. Shirai Y, Okazaki Y, Inoue Y, Tamura Y, Yasuoka H, Takeuchi T, and Kuwana M. Elevated pentraxin 3 in systemic sclerosis: Associations with vascular manifestations and defective vasculogenesis. Arthritis & Rheumatology. 67(2):pp.498-507, 2015.
  25. Nishina N, Kaneko Y, Kameda H, and Takeuchi T. The effect of tocilizumab on preventing relapses in adult-onset Still’s disease: A retro-spective, single center study. Mod Rheum. 25(3):pp.401-4, 2015.
  26. Izumi K, Kaneko Y, Yasuoka H, Seta N, Kameda H, Kuwana M, and Takeuchi T. Tocilizumab is clinically, functionally and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitrs. A single center retrospective cohort study (KEIO-TCZ study) at 52 week. Mod Rheum. 25(1):pp.31-37, 2015.
  27. Takeuchi T, Tanaka Y, Close D, Godwood A, Wu C-Y, and Saurigny D. Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: findings from phase IIa study. Mod Rheum. 25(1):pp.21-30, 2015.
  28. Takeuchi T, Yamamoto K, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N, and Koike T. Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies. Mod Rheum. 25(1):pp.11-20, 2015.
  29. Kikuchi J, Hashizume M, Kaneko Y, Yoshimoto K, Nishina N, and Takeuchi T. Peripheral blood CD4+CD25+CD127low regulatory T  cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: Increase in regulatory T cells correlates with clinical response. Arthritis Research & Therapy. 17(1):R10, 2015.
  30. Takeuchi T, Miyasaka N, Kawai S, Sugiyama N, Yuasa H, Yamashita N, Sugiyama N, Wagerle LC, Vlahos B, and Wajdula J. Pharmacokinetics, efficacy, safety profile of etanercept monotherap y in Japanese patients with rheumatoid arthritis: review of seven clinical trials. Mod Rheum. 25(2): pp.173-186, 2015.
  31. Takeuchi T, Miyasaka M, Inui T, Yano T, Yoshinari T, Abe T, and Koike T. Prediction of clinical response after one year of infliximab therapy in rheumatoid arthritis based on disease activity at three months into therapy to tailor infliximab dose: post-hoc analysis of the RISING study. J Rheumatology. 42(4):pp.599-607, 2015.
  32. Yang L, Fujimoto M, Murota H, Serada S, Fujimoto M, Honda H, Yamada K, Suzuki K, Nishikawa A, Hosono Y, Yoneda Y, Takehara K, Imura Y, Mimori T, Takeuchi T, Katayama I, and Naka T. Proteomic identification of heterogeneous nuclear ribonucleoprotein K as a novel cold-associated autoantigen in patients with secondary Raynaud’s phenomenon. Rheumatology. 54(2):pp.349-58, 2015.
  33. Kaji K, Noreen F, Medsger TA Jr, Satoh T, Hoshino K, Hamaguchi Y, Hasegawa M, Lucus M, Schnure A, Ogawa F, Sato S, Takehara K, Fujimoto M, and Kuwana M. Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement. Arthritis Care Res. 66(4):pp.575-584, 2014.
  34. Saketkoo LA, Mittoo S, Frankel S, Lesage D, Sarver C, Phillips K, Strand V, Matteson EL, OMERACT Connective Tissue Disease–Interstitial Lung Diseases Working Group, and Delphi Process Collaborators. Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease-related interstitial lung diseases. J. Rheumatol. 41(4):pp.792-798, 2014.
  35. Kaburaki J, and Kuwana M. How to detect early stage rheumatoid arthritis (RA) in persons undergoing Ningen Dock (health evaluation and promotion). Ningen Dock Int. 1(1):pp.24-33, 2014.
  36. Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, Flaherty KR, Frankel S, Oddis CV, Denton CP, Fischer A, Kowal-Bielecka OM, Lesage D, Merkel PA, Phillips K, Pittrow D, Swigris J, Antoniou K, Baughman RP, Castelino FV, Christmann RB, Christopher-Stine L, Collard HR, Cottin V, Danoff S, Highland KB, Hummers L, Shah AA, Kim DS, Lynch DA, Miller FW, Proudman SM, Richeldi L, Ryu JH, Sandorfi N, Sarver C, Wells AU, Strand V, Matteson EL, Brown KK, Seibold JR and Dephi co-authors. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax. 69(5):pp.436-444, 2014.
  37. Shirai Y, Tamura Y, Yasuoka H, Satoh T, and Kuwana M. IgG4-related disease in pulmonary arterial hypertension on longterm epoprostenol treatment. Eur Respir J. 43(5):pp.1516-1519, 2014.
  38. Washio M, Fujii T, Kuwana M, Kawaguchi Y, Mimori A, Horiuchi T, Tada Y, Takahashi H, Mimori T, and Japan MCTD study group. Lifestyle and other related factors for the development of mixed connective tissue disease among Japanese females in comparison with systemic lupus erythematosus. Mod Rheumatol. 24(5):pp.788-792, 2014.
  39. Suzuki S, Yonekawa T, Kuwana M, Hayashi YK, Okazaki Y, Kawaguchi Y, Suzuki N, and Nishino I. Clinical and histological findings associated with autoantibodies detected by RNA immunoprecipitation in inflammatory myopthies. J Neuroimmunol. 274(1-2):pp.202-208, 2014.
  40. Kuwana M. Dysregulated negative immune regulators in immune thrombocytopenia. ISBT Sci. Ser. 9:pp.217-222, 2014.
  41. Kuno T, Tamura Y, Kimura K, Ono T, Murata M, Kuwana M, Satoh T, and Fukuda K. Recurrent right atrial thrombosis due to Behçet’s disease. Can. J. Cardiol. 30(10):pp.1250.e1-3, 2014.
  42. Ito A, Nakamura Y, Saito K, Sho Y, Ishikawa K, Shimada H, Hatano Y, Okamoto O, Haranaka M, Ishii K, Nakamuro T, Kimoto K, Kuwana M, Hamaguchi Y, and Fujiwara S. Fatal case of clinically amyopathic dermatomyositis: cotton-wool spots as a sign of an aggressive subtype of dermatomyositis. J. Dermatol. 41(10):pp.943-944, 2014.
  43. Hanaoka H, Hashiguchi A, Konishi K, Ishii T, and Kuwana M. A rare association of Fabry’s disease and granulomatosis with polyangiitis: a potential pathogenic link. BMC Nephrol. 15(1):pp.157, 2014.
  44. Nishimoto T, Numajiri M, Nakazaki H, Okazaki Y, and Kuwana M. Induction of immune tolerance to platelet antigen by short-term thrombopoietin treatment in a mouse model of immune thrombocytopenia. Int. J. Hematol. 100(4):pp.341-344, 2014.
  45. Kang EH, Kuwana M, Okazaki Y, Lee EY, Lee YJ, Lee EB, and Song YW. Comparison of radioimmunoprecipitation versus antigen-specific assays for identification of myositis specific autoantibodies in dermatomyositis patients. Mod Rheumatol. 26(6):pp.945-948, 2014.
  46. Hirohata S, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M, Takeno M, and Ishigatsubo Y. Analysis of various factors on the relapse of acute neurological attacks in Behcet’s disease. Mod Rheumatol. 24(6):pp.961-965, 2014.
  47. Gono T, Kaneko H, Kawaguchi Y, Hanaoka M, Kataoka S, Kuwana M, Takagi K, Ichida H, Katsumata Y, Ota Y, Kawasumi H, and Yamanaka H. Cytokine profiles in polymyositis and dermatomyositis complicated with rapidly progressive or chronic interstitial lung disease. Rheumatology. 53(12):pp.2196-2203, 2014.
  48. Horai Y, Koga T, Fujikawa K, Takatani A, Nishino A, Nakashima Y, Suzuki T, Kawashiri S, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Ida H, Kakugawa T, Sakamoto N, Ishimatsu Y, Mukae H, Hamaguchi Y, Fujimoto M, Kuwana M, Origuchi T, Kohno S, and Kawakami A. Serum interferon-α is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis. Mod Rheumatol. 25(1):pp.85-89, 2015.
  49. Hirohata S, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M, Takeno M, and Ishigatsubo Y. Retrospective analysis of long-term outcome of chronic progressive neurological manifestations in Behçet’s disease. J. Neurol. Sci. 349(1-2):pp.143-148, 2015.
  50. Salem D, Subang R, Okazaki Y, Laplante P, Levine JS, Kuwana M, and Rauch J. 2-glycoprotein I-specific T cells are associated with epitope spread to lupus-related autoantigens in multiple MHC class II haplotypes. J. Biol. Chem. 290(9):pp.5543-5555, 2015.
  51. Kubo S, Yamaoka K, Kondo M, Yamagata K, Zhao J, Iwata S, Tanaka Y. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann Rheum Dis. 73(12):pp.2192-8, 2014.
  52. Kubo S, Saito K, Hirata S, Fukuyo S, Yamaoka K, Sawamukai N, Nawata M, Iwata S, Mizuno Tanaka Y. Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: A retrospective analysis of 6 months of abatacept treatment in routine practice. The ALTAIR study. Mod Rheumatol. 24(1):42-51, 2014.
  53. Fukuyo S, Saito K, Yamaoka K, Sawamukai N, Hirata S, Nawata M, Iwata S, Tanaka Y. Efficacy and safety of reducing duration of infliximab infusion. Mod Rheumatol. 24(2):275-80, 2014.
  54. Miyagawa I, Nakayamada S, Saito K, Hanami K, Nawata M, Sawamukai N, Nakano K, Yamaoka K, Tanaka Y. Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis. Mod Rheumatol. 24(3):405-9, 2014.
  55. Yamaoka K, Tanaka Y. Targeting the JAKs in rheumatoid arthritis; focus on tofacitinib. Expert Opin Pharmacother. 15(1):103-13, 2014.
  56. Sonomoto K, Yamaoka K, Kubo S, Hirata S, Fukuyo S, Maeshima K, Suzuki K, Saito K, Tanaka Y. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: Relation to efficacy and infectious adverse events. Rheumatology (Oxford). 53(5):914-8, 2014.
  57. Fukuyo S, Yamaoka K, Sonomoto K, Tanaka Y. IL-6 accelerated calcification by induction of ROR2 in human adipose tissue-derived mesenchymal stem cells is STAT3-dependent. Rheumatology (Oxford). 53(7):1282-90, 2014.
  58. Sonomoto K, Yamaoka K, Fukuyo S, Tanaka Y. The Role of Wnt5a/Ror2 signaling pathway in bone metabolism. Inflammation and Regeneration. 34:pp.103-108, 2014.
  59. Kubo S, Yamaoka K, Maeshima K, Tanaka Y. The possible mode of action of Tofacitinib, a JAK inhibitor. Inflammation and Regeneration. 34:pp.129-133, 2014.
  60. Sonomoto K, Yamaoka K, Tanaka Y. An approach to bone and cartilage repair of rheumatoid arthritis by mesenchymal stem cells. J UOEH. 36(2):pp.141-6, 2014
  61. Wang SP, Iwata S, Nakayamada S, Sakata K, Yamaoka K, Tanaka Y. Tofacitinib a JAK inhibitor, inhibits human B cell activation in vitro. Ann Rheum Dis. 73(12):pp. 2213-5, 2014.
  62. Kondo M, Yamaoka K, Tanaka Y. Acquiring chondrocyte phenotype from human mesenchymal stem cells under inflammatory conditions. Int J Mol Sci. 15(11):pp.21270-85, 2014.
  63. Zhangmei, Yamaoka K, Sonomoto K, Kaneko H, Satake M, Yamamoto Y, Kondo M, Zhao J, Miyagawa I, Yamagata K, Fukuyo S, Okada Y, Tanaka Y. A novel delivering system of mesenchymal stem cells using Nano-fiber scaffold for treatment of rheumatic arthritis. PLoS One. 9(12):e114621. 2014.
  64. Tanaka Y, Takeuchi T, Amano K, Saito K, Hanami K, Nawata M, Fukuyo K, Kameda H, Kaneko Y, Kurasawa T, Nagasawa H, HoshiD, Sato E, Yamanaka H. Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors. Mod Rheumol. 24(3):pp.399-404, 2014.
  65. Kaneko Y, Takeuchi T. A paradigm shift in rheumatoid arthritis over the past decade. Internal Med. 53(17):pp.1895-903, 2014.
  66. Tanaka Y, Kubo S, Yamanaka H, Amano K, Hirata S, Tanaka E, Nagasawa H, Yasuoka H, Takeuchi T. Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia(®) as Biological Intensive Treatment for RA (ORBIT) study. Mod Rheumatol. 24(5):pp.754-762, 2014.
  67. Yasuoka H, Yamaguchi Y, Feghali-Bostwick CA. The membrane-associated adaptor protein DOK5 is upregulated in systemic sclerosis and associated with IGFBP-5-induced fibrosis. PLoS One. 9(2):pp.e87754, 2014.
  68. Hanaoka H,Hashiguchi A,Konishi K,Kuwana M,Takeuchi T. An unusual association between focal segmental sclerosis
and lupus nephritis:a distinct concept from lupus podocytopathy? CEN Case Reports. 4: pp.70-5, 2015.

2013年

  1. Takeuchi T, Harigaya M, Tanaka Y, Yamanaka H, Ishiguro N, Yamamoto K, Miyasaka N, Koike T, Kanazawa M, Ohba T, Yoshinari T, Baker D, and the GO-MONO study group. Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying anti-rheumatic drugs: results of the Phase 2/3, multicenter, randomized, double-blind, placebo-controlled GO-MONO study through 24 weeks. Ann Rheum Dis. 72(9):pp.1488-95, 2013.
  2. Takeuchi T, Miyasaka N, Zang C, Alvarez D, Fletcher T, Wajdula J, Yuasa H, and Vlahos B. A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity and safety in Japanese subjects with rheumatoid arthritis. Mod Rheum. 23(4):pp.623-33, 2013.
  3. Tsuboi H, Hagiwara S, Asashima H, Umehara H, Kawakami A, Nakamura H, Sano H, Tsubota K, Ogawa Y, Takamura E, Saito I, Inoue H, Nakamura S, Moriyama M, Takeuchi T, Tanaka Y, Hirata S, Mimori T, Matsumoto I, and Sumida T. Validation of different sets of criteria for the diagnosis of Sjogren’s syndrome in Japanese patients. Mod Rheum. 23(2):pp.219-225, 2013.
  4. Nakajima A, Saitoh K, Kojima T, Amano K, Yoshio T, Fukuda W, Inoue E, Taniguchi A, Momohara S, Minota S, Takeuchi T, Ishiguro N, Tanaka Y, and Yamanaka H. No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan. Mod Rheum. 23(5):pp.945-52, 2013.
  5. Takeuchi T and Suzuki K. CD247 variants and single nucleotide polymorphisms observed in systemic lupus erythematosus patients. Rheumatology. 52(9):pp.1551-5, 2013.
  6. Nishina N, Kaneko Y, Kameda H, Kuwana M, and Takeuchi T. Reduction of plasma IL-6, but not TNF-α by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progression. Clinical Rheum. 32(11):1661-6, 2013.
  7. Kaneko Y, Kondo H, Takeuchi T. American college of rheumatology/european league against rheumatism remission criteria for rheumatoid arthritis maintain reliable performance when evaluated in 44 joints. J Rheumatol. 40(8):pp.1254-58, 2013.
  8. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Hirose T, Yoshinaga T, and Suzukawa M. Safety and effectiveness of 6 months etanercept monotherapy and combination therapy in Japanese patients with Rheumatoid Arthritis: Effect of concomitant disease-modifying anti-rheumatic drugs. J Rheumatology. 40(10):pp.1658-68, 2013.
  9. Kaneko Y, Kuwana M, Takeuchi T, and Oddis CV. Osteolytic change of distal interphalangeal joints and sacroiliac joints in subluxing arthropathy associated with anti-Jo-1 antibody.Joint Bone Spine. 80(5):pp.544-5, 2013.
  10. Takeuchi T, Kawai S, Yamamoto K, Harigai M, Ishida K, and Miyasaka M. Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3267 Japanese patients with rheumatoid arthritis. Mod Rheum. 24(1):pp.8-16, 2014.
  11. Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T, Uchida S, Akama H, Hartmut K, Vipin A, and Tanaka Y. Adalimumab, a Human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early RA; the HOPEFUL 1 study. Ann Rheum Dis. 73(3):pp.536-543, 2014.
  12. Nishina N, Kikuchi J, Hashizume M, Yoshimoto K, Kameda H, and Takeuchi T. Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy. Ann Rheum Dis. 73(5):pp.945-7, 2014.
  13. Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M, Iwamoto M, Kohsaka H, Kondo M, Matsubara T, Mimura T, Miyahara H, Ohta S, Saeki Y, Saito K, Sano H, Takasugi K, Takeuchi T, Tohma S, Tsuru T, Ueki Y, Yamana J, Hashimoto J, Matsutani T, Murakami M, Takagi N. Drug free REmission/low disease activity after cessasion of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheum. 24(1):pp.17-25, 2014.
  14. Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M, Iwamoto M, Kohsaka H, Kondo M, Matsubara T, Mimura T, Miyahara H, Ohta S, Saeki Y, Saito K, Sano H, Takasugi K, Takeuchi T, Tohma S, Tsuru T, Ueki Y, Yamana J, Hashimoto J, Matsutani T, Murakami M, Takagi N. Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study. Mod Rheum. 24(1):pp.26-32, 2014.
  15. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Takei S, Tanaka Y, Sano Y, Yamaguchi H, and Yamanaka H. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatology. 41(1):pp.15-23, 2014.
  16. Nishimoto T, Seta N, Anan R, Yamamoto T, Kaneko Y, Takeuchi T, and Kuwana M. A single nucleotide polymorphism of TRAF1 predicts the clinical response to anti-TNF treatment in Japanese patients with rheumatoid arthritis. Clin Exp Rheum. 32(2):pp.211-7, 2014.
  17. Yamanaka H, Ishiguro N, Takeuchi, T, Miyasaka N, Mukai M, Matsubara T, Uchida S, Akama H, Kupper H, Arora V, and Tanaka Y. Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial. Rheumatology. 53(5):pp.904-13, 2014.
  18. Mok CC, Yap DY, Navarra SV, Liu Z-H, Zao M-H, Lu L, Takeuchi T, Avihingsanon Y, Yu X-Q, Lapid EA, Lugue-Lizardo LR, Smethkul V, Shen N, Chen S-L, and Chan TM, for the Asian Lupus Nephritis Network. Overview of lupus nephritis management guidelines and perspective from Asia. Nephrology. 19(1):pp.11-20, 2014.
  19. Kaneko Y, Kuwana M, Kondo H, and Takeuchi T. Discordance in global assessments between patient and estimator in patients with newly diagnosed rheumatoid arthritis: associations with progressive joint destruction and functional impairment. J Rheumatology. 41(6):pp.1061-6, 2014.
  20. Azuma N, Nishioka A, Kuwana M, and Sano H. Relapsing polychodritis coexisting with immune thrombocytopenic purpura: an unusual association. Rheumatology. 52(4):pp.757-9, 2013.
  21. Hara S, Henmi T, Kawakami A, Fujikawa K, Mukae H, Ishimatsu Y, Sakamoto N, Kakugawa T, Kaji K, Fujimoto M, Kuwana M, Tsukada T, Satoh K, Motomura M, Tamai M, Nakamura H, Ida H, Hayashi T, Origuchi T, Eguchi K, and Kohno S. Clinical, serologic and magnetic resonance imaging of 3 cases of inflammatory myopathy with abundant macrophages in the Japanese population. Rheumatol Int. 33(4): pp.1059-64, 2013.
  22. Hamaguchi Y, Fujimoto M, Matsushita T, Kaji K, Komura K, Hasegawa M, Kodera M, Muroi E, Fujikawa K, Seishima M, Yamada H, Yamada R, Sato S, Takehara K, and Kuwana M. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One. 8(4): e60442, 2013.
  23. Suzuki S, Nishimoto T, Kohno M, Utsugisawa K, Nagane Y, Kuwana M, and Suzuki N. Clinical and immunological predictors of prognosis for Japanese patients with thymoma-associated myasthenia gravis. J. Neuroimmunol. 258(1-2):pp.61-6, 2013.
  24. Mitsunaga S, Hosomichi K, Okudaira Y, Nakaoka H, Kunii N, Suzuki Y, Kuwana M, Sato S, Kaneko Y, Homma Y, Kashiwase K, Azuma F, Kulski JK, Inoue T, and Inoko H. Exome-sequencing identifies novel rheumatoid arthritis-susceptible variants in the BTNL2. J. Hum. Genet. 58(4):pp. 210-5, 2013.
  25. Sato S, Kuwana M, Fujita T, and Suzuki Y. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod. Rheumatol. 23(3): pp.496-502, 2013.
  26. Masuda A, Yasuoka H, Satoh T, Okazaki Y, Yamaguchi Y, and Kuwana M. Versican is upregulated in circulating monocytes in patients with systemic sclerosis and amplifies a CCL2-mediated pathogenic loop. Arthritis Res Ther. 15(4): R74, 2013.
  27. Chen Z, Cao M, Nieves Plana M, Liang J, Cai H, Kuwana M, and Sun L. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and meta-analysis. Arthritis Care Res. 65(8):pp.1316-24, 2013.
  28. Kuwana M, Watanabe H, Matsuoka N, and Sugiyama N. Pulmonary arterial hypertension associated with connective tissue disease: meta-analysis of clinical trials. BMJ Open. 3(8): e003113, 2013.
  29. Kawai M, Ogawa Y, Shimmura S, Oota S, Suzuki T, Kawamura N, Kuwana M, Kawakami Y, and Tsubota K. Expression and localization of aging markers in lacrimal gland of chronic graft-versus-host disease. Sci. Rep. 3: 2455, 2013.
  30. Satoh T, Miyazaki K, Shimohira A, Amano N, Okazaki Y, Nishimoto T, Akahoshi T, Munekata S, Kanoh Y, Ikeda Y, Higashihara M, Takahashi S, and Kuwana M. Fc receptor IIB gene polymorphism in adult Japanese patients with primary immune thrombocytopenia (letter). Blood. 122(11):pp.1991-2, 2013.
  31. Seta N, Okazaki Y, Miyazaki H, Kato T, and Kuwana M. Platelet-derived stromal cell-derived factor-1 is required for the transformation of circulating monocytes into multipotential cells. PLoS One. 8(9): e74246, 2013.
  32. Hasegawa M, Asano Y, Endo H, Fujimoto M, Goto D, Ihn H, Inoue K, Ishikawa O, Kawaguchi Y, Kuwana M, Ogawa F, Takahashi H, Tanaka S, Sato S, and Takehara K. Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: a multicentre, prospective, observational study. Mod. Rheumatol. 23(6):pp.1076-84, 2013.
  33. Shirai Y, Yasuoka H, Takeuchi T, Satoh T, and Kuwana M. Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center. Mod. Rheumatol. 23(6):pp.1211-20, 2013.
  34. Kuwana M. Helicobacter pylori-associated immune thrombocytopenia: clinical features and pathogenic mechanisms. World J. Gastroenterol. 20(3):pp.714-23, 2014.
  35. Kuwana M, Okazaki Y, and Ikeda Y. Detection of circulating B cells producing anti-GPIb autoantibodies in patients with immune thrombocytopenia. PLoS One. 9(1): e86943, 2014.
  36. Hasegawa M, Asano Y, Endo H, Fujimoto M, Goto D, Ihn H, Inoue K, Ishikawa O, Kawaguchi Y, Kuwana M, Ogawa F, Takahashi H, Tanaka S, Sato S, and Takehara K. Serum adhesion molecule levels as prognostic markers in patients with early systemic sclerosis: a multicentre, prospective, observational study. PLoS One. 9(2): e88150, 2014.
  37. Suzuki S, Baba A, Kaida K, Utsugisawa K, Kita Y, Tsugawa J, Ogawa G, Nagane Y, Kuwana M, and Suzuki N. Cardiac involvements in myasthenia gravis associated with anti-Kv1.4 antibodies. Eur. J. Neurol. 21(2):pp.223-30, 2014.
  38. Kubo A, Azuma A, Kanazawa M, Kameda H, Kusumoto M, Genma A, Saijo Y, Sakai F, Sugiyama Y, Tatsumi K, Dohi M, Tokuda H, Hashimoto S, Hattori N, Hanaoka M, Fukuda Y. Japanese Respiratory Society Committee for formulation of Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Invest. 51:pp.260-277, 2013.
  39. Tanaka Y, Takeuchi T, Amano K, Saito K, Hanami K, Nawata M, Fukuyo S, Kameda H, Kaneko Y, Kurasawa T, Nagasawa H, Hoshi D, Sato E, Yamanaka H. Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors. Mod Rheumatol. 24:pp.399-404, 2014.
  40. Aida-Yasuoka K, Peoples C, Yasuoka H, Hershberger P, Thiel K, Cauley JA, Medsger TA Jr, Feghali-Bostowick CA. Estradiol promotes the development of a fibrotic phenotype and is increased in the serum of patients with systemic sclerosis. Arthritis Res Ther.15:R10, 2013.
  41. Shirai Y, Tamura Y, Yasuoka H, Satoh T, Kuwana M. IgG4-related disease in pulmonary arterial hypertension on longterm epoprostenol treatment. Eur Respir J. 43(5):pp.1516-9, 2014.
  42. Yasuoka H, Yamaguchi Y, Feghali-Bostwick CA. The membrane-associated adaptor protein DOK5 is upregulated in systemic sclerosis and associated with IGFBP-5-induced fibrosis. PLOS one 9:e87754, 2014.
  43. Kurasawa T, Nagasawa H, Nishi E, Takei H, Okuyama A, Kondo T, Nishimura K, Sakai R, Shibata A, Chino K, Ogawa H, Ito T, Amano K, Kato H. Succeccful treatment of class Ⅳ+Ⅴ lupus nephritis with combination therapy of high-dose corticosteroids, tacrolimus and intravenous cyclophosphamide. Intern Med. 52(10):pp.1125-50(Epub 2013 May)
  44. Shimane K, Kochi Y, Suzuki A, Okada Y, Ishii, T., Horita T, Saito, K., Okamoto A, Nishimoto N, Myouzen K, Kubo M, Hirakata M, Sumida T, Takasaki Y, Yamada R, Nakamura Y, Kamatani N, Yamamoto K. An association analysis of HLA-DRB1 with systemic lupus erythematosus and rheumatoid arthritis in a Japanese population: effects of *09:01 allele on disease phenotypes. Rheumatology (Oxford). 52(7):pp.1172-82, 2013.
  45. Nakashima R, Imura Y, Hosono Y, Seto M, Murakami A, Watanabe K, Handa T, Mishima M, Hirakata M, Takeuchi T, Fujio K, Yamamoto K, Kohsaka H, Takasaki Y, Enomoto N, Suda T, Chida K, Hisata S, Nukiwa T, Mimori T. The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia. PLoS One. 14;9(1) :e85062, 2014.

2012年

  1. Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T, Uchida S, Akama H, Hartmut K, Vipin A, and Tanaka Y. Adalimumab, a Human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early RA; the HOPEFUL 1 study. Ann Rheum Dis online January 11, 2013.
  2. Tsuboi H, Hagiwara S, Asashima H, Umehara H, Kawakami A, Nakamura H,Sano H,Tsubota K,Ogawa Y,Takamura E,Saito I,Inoue H,Nakamura S,Moriyama M,Takeuchi T,Tanaka Y, Hirata S, Mimori T, Matsumoto I, and Sumida T.Validation of different sets of criteria for the diagnosis of Sjogren’s syndrome in Japanese patients. Mod Rheum 23:pp.219-225, 2013.
  3. Takeuchi T and Suzuki K. CD247 variants single nucleotide polymorphisms observed in systemic lupus erythematosus. Rheumatology online March 22, 2013.
  4. Takeuchi T, Matsubara T, Nitobe T, Suematsu E, Ohta S, Honjyo S, Abe T, Yamamoto A, Miyasaka N, and The Japan Abatacept Study Group. Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with inadequate response to methotrexate. Mod Rheum 23:pp.226-235, 2013.
  5. Koike T, Harigaya M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, Yamanaka H, and Tanaka Y. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: post marketing surveillance report of the first 3,000 patients. Mod Rheum 22:pp.498-508, 2012.
  6. Takeuchi T, Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T, and Koike T. Inhibition of plasma IL-6 in addition to maintain efficacious trough level of infliximab was associated with clinical remission in patients with rheumatoid arthritis: analysis of the RISING Study. Ann Rheum Dis, 71:pp.1583-85, 2012.
  7. Takeuchi T and Kameda H. What is the future of CCR5 antagonists? Arthritis Research and Therapy 14: R11, 2012.
  8. Takeuchi T, Suzuki K, Kondo T, Yoshimoto K, and Tsuzaka K. CD3  defects in systemic lupus erythematosus. Ann Rheum Dis 71:i78-i81, 2012.
  9. Harigai M, Takeuchi T, Tanaka Y, Matsubara T, Yamanaka H, and Miyasaka N. Discontiuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Mod Rheum 22: pp.814-22, 2012.
  10. Nishi E, Kameda H, Ogawa H, Nagasawa H, Takei H, Okuyama A, Kurasawa T, Kondo T, Nishimura K, Shirai Y, Sakai R, Ito T, Takeuchi T, and Amano K. Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis. Mod Rheum 23:pp.97-103,2013
  11. Niki Y, Takeuchi T, Masanori Nakayama, Hayato Nagasawa, Takahiko Kurasawa, Harumoto Yamada, Toyama Y, and Takeshi Miyamoto. Clinical Significance of Cartilage Biomarkers for Monitoring Structural Joint Damage in Rheumatoid Arthritis Patients Treated with Anti-TNF Therapy. PLoS ONE 7:e37447, 2012.
  12. Sakai R, Nagasawa H, Nishi E, Okuyama A, Takei H, Kurasawa T, Kondo T, Nishimura K, Shirai Y, Ito T, Kameda H, Takeuchi T, and Amano K. Successful treatment of adult-onset Still’s disease with tocilizumab monotherapy: two case reports with literature review. Clin Rheum 31:pp.569-74, 2012.
  13. Takeuchi T, Harigaya M, Tanaka Y, Yamanaka H, Ishiguro N, Yamamoto K, Miyasaka N, Koike T, Kanazawa M, Ohba T, Yoshinari T, Baker D, and the GO-MONO study group. Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying anti-rheumatic drugs: results of the Phase 2/3, multicenter, randomized, double-blind, placebo-controlled GO-MONO study through 24 weeks. Ann Rheum Dis online September 14, 2012.
  14. Takeuchi T, Miyasaka N, Zang C, Alvarez D, Fletcher T, Wajdula J, Yuasa H, and Vlahos B. A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity and safety in Japanese subjects with rheumatoid arthritis. Mod Rheum online September 26, 2012.
  15. Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, Tsukano M, Kasama T, Shiozawa S, Tanaka Y, Yamanaka H, and Takeuchi T, Japan Biological Agent Integrated Consortium (JBASIC).A merged presentation of clinical and radiographic data using probability plots in a clinical trial, the JESMR study. Ann Rheum Dis 72:pp.310-2, 2012.
  16. Tanaka Y, Yamanaka H, Saito K, Iwata S, Miyagawa I, Seto Y, Momohara S, Nagasawa H, Kameda H, Kaneko Y, Izumi K, Amano K, and Takeuchi T. Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept. Mod Rheum, 22:pp.186-94, 2012.
  17. Takeuchi T, Tanaka Y, Kaneko Y, Tanaka E, Hirata S, Kurasawa T, Kubo S, Shidara K, Kimura N, Nagasawa H, Kameda H, Amano K, and Yamanaka H. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: Retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheum, 22:pp.327-338, 2012.
  18. Tanaka Y, Harigaya M, Takeuchi T, Yamanaka H, Ishiguro N, Yamamoto K, Miyasaka N, Koike T, Kanazawa M, Ohba T, Yoshinari T, Baker D, and the GO-FORTH study group. Golimumab, a human anti-TNF- monoclonal antibody, injected subcutaneously every 4 weeks in Japanese patients with active rheumatoid arthritis in combination methotrexate: results of the Phase 2/3, multicenter, randomized, double-blind, placebo-controlled GO-FORTH study through 24 weeks. Ann Rheum Dis, 71:pp.817-24, 2012.
  19. Kuwana M, and Okazaki Y. Quantification of circulating endothelial progenitor cells in systemic sclerosis: a direct comparison of protocols. Ann Rheum Dis. 71(4): pp.617-620, 2012.
  20. Nishimoto T, Satoh T, Takeuchi T, Ikeda Y, and Kuwana M. Critical role of CD4+CD25+ regulatory T cells in preventing murine autoantibody-mediated thrombocytopenia. Exp Hematol. 40(4): pp.279-289, 2012.
  21. Ichimura Y, Matsushita T, Hamaguchi Y, Kaji K, Hasegawa M, Tanino Y, Inokoshi Y, Kawai K, Kanekura T, Habuchi M, Igarashi A, Sogame R, Hashimoto T, Koga T, Nishino A, Ishiguro N, Sugimoto N, Aoki R, Ando N, Abe T, Kanda T, Kuwana M, Takehara K, and Fujimoto M. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis. 71(5): pp.710-713, 2012.
  22. Mitsunaga S, Suzuki Y, Kuwana M, Sato S, Kaneko Y, Homma Y, Narita A, Kashiwase K, Okudaira Y, Inoue T, Kulski JK, and Inoko H. Associations between six classical HLA loci and rheumatoid arthritis: a comprehensive analysis. Tissue Antigens. 80(1): pp.16-25, 2012.
  23. Hirohata S, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M, Takeno M, and Ishigatsubo Y. Clinical characteristics of neuro-Behcet’s disease in Japan: a multicenter retrospective analysis. Mod Rheumatol. 22(3): pp.405-413, 2012.
  24. Suzuki S, Hayashi Y, Kuwana M, Tsuburaya R, Suzuki N, and Nishino I. Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome. Arch Neurol. 69(6): pp.728-732, 2012.
  25. Miyasaka N, Hara M, Koike T, Saito E, Yamada M, Tanaka Y, GB-0998 Study Group. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Mod Rheumatol. 22(3): pp.382-393, 2012.
  26. Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri S, Iwamoto N, Suzuki T, Nakashima Y, Tamai M, Arima K, Yamasaki S, Nakamura H, Origuchi T, Hamaguchi Y, Fujimoto M, Ishimatsu Y, Mukae H, Kuwana M, Kohno S, Eguchi K, and Kawakami A. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with dermatomyositis. Rheumatology. 51(7): pp.1278-1284, 2012
  27. Nakajima A, Yoshino K, Soejima M, Kawaguchi Y, Satoh T, Kuwana M, and Yamanaka H. High Frequencies and co-existing of myositis-specific autoantibodies in patients with idiopathic inflammatory myopathies overlapped to rheumatoid arthritis. Rheumatol Int. 37(2): pp.2057-2061, 2012.
  28. Nishina N, Kaneko Y, Kuwana M, Hanaoka H, Kameda H, Mikami S, and Takeuchi T. IgG4-related disease without IgG4 over-expression: pathogenesis implications. Case Report Rheumatol. 2012: pp.754935, 2012.
  29. Sato S, Kuwana M, Fujita T, and Suzuki Y. Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies. Mod Rheumatol. 22(4): pp.625-629, 2012.
  30. Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, Takagi K, Baba S, Okamoto Y, Ota Y, and Yamanaka H. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology. 51(9): pp.1563-1570, 2012.
  31. Satoh T, Tanaka Y, Okazaki Y, Kaburaki J, Ikeda Y, and Kuwana M. Heparin-dependent and -independent anti-platelet factor 4 autoantibodies in patients with systemic lupus erythematosus. Rheumatology. 51(9): pp.1721-1728, 2012.
  32. Tamura Y, Ono T, Kuwana M, Inoue K, Takei M, Yamamoto T, Kawakami T, Fujita J, Kataoka M, Kimura K, Sano M, Daida H, Satoh T, and Fukuda K. Human pentraxin 3 (PTX3) as a novel biomarker for the diagnosis of pulmonary arterial hypertension. PLoS One. 7(9): pp.e45834, 2012.
  33. Shirai Y, Yasuoka H, Okano Y, Takeuchi T, Satoh T, and Kuwana M. Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a single-center cohort. Rheumatology. 51(10): pp.1846-1854, 2012.
  34. Hanaoka H, Okazaki Y, Satoh T, Kaneko Y, Yasuoka H, Seta N, and Kuwana M. Circulating anti-double-stranded DNA antibody-secreting cells in patients with systemic lupus erythematosus: a novel biomarker for disease activity. Lupus. 21(12): pp.1284-1293, 2012.
  35. Cao H, Xia Q, Kang Y, Zhao X, Shi R, Lou J, Zhou M, Kuwana M, Ding X, and Zheng J. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-MDA5 antibody. Arthritis Care Res. 64(10): pp.1602-1610, 2012.
  36. Matsuura E, Ishiguro N, Katsumata Y, Urano W, Yamanaka H, Kondo M, Kuwana M, Kaji K, Hamaguchi Y, Fujimoto M, and Kawashima M. Two young-adult female cases of dermatomyositis with antibodies for transcriptional intermediary factor 1-. Eur J Dermatol. 22(5): pp.668-671, 2012.
  37. Seta N, Okazaki Y, Izumi K, Miyazaki H, Kato T, and Kuwana M. Fibronectin binding is required for acquisition of mesenchymal/endothelial differentiation potential in human circulating monocytes. Clin Dev Immunol. 2012: pp.820827, 2012.
  38. Gono T, Kawaguchi Y, Kuwana M, Sugiura T, Furuya T, Takagi K, Ichida H, Katsumata Y, Hanaoka M, Ota Y, and Yamanaka H. Association of HLA-DRB1*0101/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum. 64(11): pp.3736-3740, 2012.
  39. Yasuoka H, and Kuwana M. Combined interstitial lung disease and pulmonary hypertension in systemic sclerosis: pathophysiology and management. CML-Pulmonary Hypertension. 3(4): pp.105-115, 2012.
  40. Horai Y, Isomoto E, Koga T, Okada A, Kawashiri S, Tamai M, Yamasaki S, Nakamura H, Origuchi T, Hamaguchi Y, Fujimoto M, Kuwana M, and Kawakami A. Early diagnosis and treatment for remission of clinically amyopathic dermatomyositis complicated by rapid progress interstitial lung disease: a report of two cases. Mod Rheumatol. 23(1): pp.190-194, 2013.
  41. Yamaguchi Y, and Kuwana M. Proangiogenic hematopoietic cells of monocytic origin: roles in vascular regeneration and pathogenic processes of systemic sclerosis. Histol Histopathol. 28(2): pp.175-183, 2013.
  42. Terao C, Ohmura K, Kawaguchi Y, Nishimoto T, Kawasaki A, Takehara K, Furukawa H, Kochi Y, Ota Y, Ikari K, Sato S, Tohma S, Yamada R, Yamamoto K, Kubo M, Yamanaka H, Kuwana M, Tsuchiya N, Matsuda F, and Mimori T. PLD4 as a novel susceptibility gene for systemic sclerosis in a Japanese population. Arthritis Rheum. 65(2): pp.472-480, 2013.
  43. Nishimoto T, Satoh T, Simpson EK, Ni H, and Kuwana M. Predominant autoantibody response to GPIb/IX in a regulatory T-cell-deficient mouse model for immune thrombocytopenia. J Thromb Haemost. 11(2): pp.369-372, 2013.
  44. Tanaka Y, Yamanaka H, Saito K, Iwata S, Miyagawa I, Seto Y, Momonara S, Nagasawa H, Kameda H, Kaneko Y, Izumi K, Amano K, Takeuchi T. Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept. Mod Rheumatol 2012;22:186-194.
  45. Tokuhira M, Watanabe R, Nemoto T, Sagawa M, Tomikawa T, Tamaru J-I, Itoyama S, Nagasawa H, Amano K, Kameda H, Takeuchi T, Mori S, Kizaki M. Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis. Leuk Lymphoma 2012;53:616-623.
  46. Takamura A, Hirata S, Nagasawa H, Kameda H, Seto Y, Atsumi T, Dohi M, Koike T, Miyasaka N, Harigai M. Elevation of KL-6 serum levels in clinical trials of tumor necrosis factor inhibitors in patients with rheumatoid arthritis – a report from the ad-hoc committee for safety of biological DAMRDs of the Japan College of Rheumatology. Mod Rheumatol 2013;23:297-303.
  47. Harigai M, Takamura A, Atsumi T, Dohi M, Hirata S, Kameda H, Nagasawa H, Seto Y, Koike T, Miyasaka N. A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients – a report from the ad-hoc committee for safety of biological DMARDs of the Japan College of Rheumatology. Mod Rheumatol 2013;23:284-296.
  48. Imura Y, Shirai Y, Nojima T, Nakashima R, Yamagata H, Miyachi K, Yoshifuji H, Kawabata D, Ohmura K, Usui T, Fujii T, Mimori T. NEFA/nucleobindin-2 is a target autoantigen of the anti-Wa antibody and is associated with transfer RNA. Mod Rheumatol. 22(5):pp.685-94,2012
  49. Takei H, Nagasawa H, Sakai R, Nishimura K, Kurasawa T, Okuyama A, Nishi E, Shirai Y, Kondo T, Ogawa H, Ito T, Amano K. A case of multiple giant coronary aneurysms and abdominal aortic aneurysm coexisting with IgG4-related disease. Intern Med.51(8):pp.963-7,2012
  50. Nishimoto T, Kuwana M. CD4(+)CD25(+)Foxp3(+) Regulatory T Cells in the Pathophysiology of Immune Thrombocytopenia. Semin Hematol. 50 Suppl 1: pp.S43-9, 2013.

2011年

  1. Niki Y, Takeuchi T, Nakayama M, Nagasawa H, Kurasawa T, Yamada H, Toyama Y, and Miyamoto T. Clinical Significance of Cartilage Biomarkers for Monitoring Structural Joint Damage in Rheumatoid Arthritis Patients Treated with Anti-TNF Therapy. PLoS ONE 7:e37447, 2012
  2. Takeuchi T and Kameda H. What is the future of CCR5 antagonists? Arthritis Res Ther. 14: R11, 2012.
  3. Koike T, Harigaya M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, Yamanaka H, and Tanaka Y. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: post marketing surveillance report of the first 3,000 patients. Mod Rheum. on line Oct. 13, 2011.
  4. Kameda H, Tokuda H, Sakai F, Johkoh T, Mori S, Yoshida Y, Takayanagi N, Takai H, Hasegawa Y, Hatta K, Yamanaka H, Dohi M, Hashimoto S, Yamada H, Kawai S, Takeuchi T, Tateda K, and Goto H. Clinical and radiological features of acute-onset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents: Importance of pneumocyctis pneumonia in Japan revealed by a multicenter study. Intern Med. 50:pp.305-313, 2011.
  5. Kawai S, Takeuchi T, Yamamoto K, Tanaka Y, and Miyasaka N. Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis patients with inadequate response to DMARDs - a multi-center, double blind, parallel-group trial. Mod Rheum. 21:pp.458-468, 2011.
  6. Yoshimoto K, Tanaka M, Kojima M, Setoyama Y, Kameda H, Suzuki K, Tsuzaka K, Ogawa Y, Tsubota K, Abe T, and Takeuchi T. Regulatory mechanism of BAFF and IL-6 are impaired in monocytes of patients of primary Sjogren’s syndrome. Arthritis Res Ther. 13:R170, 2011.
  7. Haraoui B, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Codreanu C, Da Silva JP, de Wit M, Dougados M, Durez P, Emery P, Fonseca JE, Gibfsky A, Gomez-Reino J, Graninger W, Hamuryudan V, Jannaut Peya MJ, Kalden J, Kvien TK, Laurindo I, Martin-Mola E, Montecucco C, Moreno PS, Pavelka K, Poor G, Cardiel MH, Stanislawska-Biernat E, Takeuchi T, van der Heijde D, and the Treat to Target Taskforce. Treating Rheumatoid Arthritis to Target: multinational recommendatios assessment questionnaire. Ann Rheum Dis. on line Jul. 29, 2011.
  8. Kawai S, Takeuchi T, Yamamoto K, Tanaka Y, and Miyasaka N. Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis patients with inadequate response to DMARDs – a multi-center, double blind, parallel-group trial. Mod Rheum. 21:pp.458-468, 2011.
  9. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Fujii K, Fruendlich B, and Suzukawa M. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with Rheumatoid Arthritis. Mod Rheum. 21:pp.343-351, 2011.
  10. Takeuchi T. Revolutionary change in rheumatoid arthritis management with biological therapy. Keio J Med. 60:pp.75-81, 2011.
  11. Takeuchi T, Tanaka Y, Amano K, Hoshi D, Nawata M, Nagasawa H, Satoh E, Saitao K, Kaneko Y, Fukuyo S, Kurasawa T,Hanami K, Kameda H, and Yamanaka H. Clinical, radiographic, and functional effectiveness of tocilizumab for rheumatoid arthritis patients -REACTION-52 weeks study. Rheumatology. 50:pp.1908-15, 2011.
  12. Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, Tsukano M, Kasama T, Shiozawa S, Tanaka Y, Yamanaka H, and Takeuchi T. Continuation of Methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with Rheumatoid Arthritis: 52-Week results from the JESMR Study. J Rheum. 38:pp.1585-92, 2011.
  13. Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasana N, and Harigai M. Incidence and risk factors for serious infection in rheumatoid arthritis patients treated with tumor necrosis factor (TNF) inhibitors: a report from the registry of Japanese Rheumatoid Arthritis Patients for Long-Term Safety. J Rheum. on line Apr. 15, 2011.
  14. Takeuchi T, Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T, and Koike T. Significance of the baseline plasma TNF-alpha level in different doses of infliximab for patients with rheumatoid arthritis. Ann Rheum Dis. 70:pp.1208-15, 2011.
  15. Kaneko Y, Kuwana M, Kameda H, and Takeuchi T. Sensitivity and Specificity of 2010 Rheumatoid Arthritis Classification Criteria. Rheumatology. 50:pp.1268-74, 2011.
  16. Suzuki K, Setoyama Y, Yoshimoto K, Tsuzaka K, Abe T, and Takeuchi T. Decreased mRNA expression of two Foxp3 isoforms in peripheral blood mononuclear cells from patients with rheumatoid arthritis and systemic lupus erythematosus. Int J Immunopathol and Pharmacology. 24:pp.7-14, 2011.
  17. Hashimoto J, Garnero P, van der Heijde, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, and Yoshikawa H, and Nishimoto N. Humanized anti-interleukin 6 receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomakers, radiography, and BMI: data from the SAMURAI study. Mod Rheum. 21:pp.10-15, 2011.
  18. Yamanaka H, Tanaka Y, Inoue E, Hoshi D, Momohara S, Hanami K, Yunoue N, Saito K, Amano K, Kameda H, and Takeuchi T. Efficacy of tocilizumab for rheumatoid arthritis patients in daily practice in Japan –message from REACTION study. Mod Rheum. 21:pp.122-33, 2011.
  19. Okuyama A, Nagasawa H, Suzuki K, Kameda H, Kondo H, Amano K, and Takeuchi T. Fc gamma receptor IIIb polymorphism and usage of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis. 70:pp.299-304, 2011.
  20. Tokuhira M, Watanabe R, Nemoto T, Sagawa M, Tomikawa T, Tamaru J-I, Itoyama S, Nagasawa H, Amano K, Kameda H, Takeuchi T, Mori S, Kizaki M. Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis. Leuk Lymphoma. 53:pp.616-623, 2012.
  21. Sakai R, Nagasawa H, Nishi E, Okuyama A, Takei H, Kurasawa T, Kondo T, Nishimura K, Shirai Y, Ito T, Kameda H, Takeuchi T, Amano K. Successful treatment of adult-onset Still’s disease with tocilizumab monotherapy: two case reports and literature review. Clin Rheumatol. 31:pp.569-574, 2012.
  22. Kobayashi I, Okura Y, Yamada M, Kawamura N, Kuwana M, and Ariga T. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr. 158(4): pp.675-677, 2011.
  23. Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, Komura K, Nakamura M, Kodera M, Suga N, Higashi A, Ogusu K, Tsutusi K, Furusaki A, Tanabe H, Sasaoka S, Muro Y, Yoshikawa M, Ishiguro N, Ayano M, Muroi E, Fujikawa K, Umeda Y, Kawase M, Mabuchi E, Asano Y, Sodemoto K, Seishima M, Yamada H, Sato S, Takehara K, and Fujimoto M. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multi-centre, cross-sectional study. Arch Dermatol. 147(4): pp.391-398, 2011.
  24. Hoshino K, Satoh T, Kawaguchi Y, and Kuwana M. Association of Hepatocyte Growth Factor promoter polymorphism with severity of interstitial lung disease in Japanese patients with systemic sclerosis. Arthritis Rheum. 63(8): pp.2465-2472, 2011.
  25. Suzuki S, Utsugisawa K, Iwasa K, Satoh T, Nagane Y, Yoshikawa H, Kuwana M, and Suzuki N. Autoimmunity to endoplasmic reticulum chaperone GRP94 in myasthenia gravis. J Neuroimmunol. 237(1-2): pp.87-92, 2011.
  26. Takahashi H, Kouno M, Nagao K, Wada N, Hata T, Nishimoto S, Iwakura Y, Yoshimura A, Yamada T, Kuwana M, Fujii H, Koyasu S, and Amagai M. Desmoglein 3-specific CD4+ T cells induce pemphigus vulgaris and interface dermatitis in mice. J Clin Invest. 121(9): pp.3677-3688, 2011.
  27. Ikeda N, Takahashi K, Yamaguchi Y, Inasaka M, Kuwana M, and Ikezawa Z. Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients. J Dermatol. 38(10): pp.973-979, 2011.
  28. Furuya Y, and Kuwana M. Effect of bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study. J Rheumatol. 38(10): pp.2186-2192, 2011.
  29. Noda S, Asano Y, Tamaki Z, Hirabayashi M, Yamamoto M, Takekoshi T, Hoashi T, Sugaya M, Morimoto R, Eto T, Kaji K, Fujimoto M, Kuwana M, and Sato S. Dermatomyositis with anti-OJ antibody. Rheumatol Int. 31(12): pp.1673-1675, 2011.
  30. Hasegawa M, Asano Y, Endo H, Fujimoto M, Goto D, Ihn H, Inoue K, Ishikawa O, Kawaguchi Y, Kuwana M, Muro Y, Ogawa F, Tanaka S, Takehara K, and Sato S. Investigation of prognostic factors for skin sclerosis and lung function in Japanese patients with early systemic sclerosis: a multicenter prospective observational study. Rheumatology. 51(1): pp.129-133, 2012.
  31. Seta N, and Kuwana M. Potential involvement of human circulating CD14+ monocytes in tissue repair and regeneration. Inflam Regen. 32(1): pp.1-7, 2012.
  32. Hattori H, Suzuki S, Okazaki Y, Suzuki N, and Kuwana M. Intracranial transplantation of monocyte-derived multipotential cells enhances recovery after ischemic stroke in rats. J Neurosci Res. 90(2): pp.479-488, 2012.
  33. Harigai M, Tanaka Y, Maisawa S, and The JA21963 Study Group. Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: A placebo-controlled double-blind parallel-group study. J Rheumatol. 39(3): pp.486-495, 2012.
  34. Yamaguchi Y, Yasuoka H, Stolz DB, Feghali-Bostwick CA. Decreased caveolin-1 levels contribute to fibrois and deposition of extracellular IGFBP-5. J Cell Mol Med. 15:pp.957-969, 2011.
  35. Imura Y, Shirai Y, Nojima T, Nakashima R, Yamagata H, Miyachi K, Yoshifuji H, Kawabata D, Ohmura K, Usui T, Fujii T, Mimori T. NEFA/nucleobindin-2 is a target autoantigen of the anti-Wa antibody and is associated with transfer RNA. Mod Rheumatol. 2012. [Epub ahead of print]
  36. Okada Y, Shimane K, Kochi Y, Tahira T, Suzuki A, Higasa K, Takahashi A, Horita T, Atsumi T, Ishii T, Okamoto A, Fujio K, Hirakata M, Amano H, Kondo Y, Ito S, Takada K, Mimori A, Saitio K, Kamachi M, Yamamoto K, et al. A Genome-wide association study identified AFF1 as a susceptibility locus for systemic lupus erythematosus in Japanese. PloS Genetics 8(1):pp.1-10, 2012.

2010年

  1. Ogawa H, Kameda H, Amano K, and Takeuchi, T. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus. 19:pp.162-169, 2010.
  2. Suzuki K, Tamaru J, Okuyama A, Kameda H, Amano K, Nagasawa H, Nishi, E, Yoshimoto K, Setoyama Y, Kaneko K, Osada H, Honda N, Sasaki Y, Itoyama S, Tsuzaka K, and Takeuchi T. IgG4-positive multi-organ lymphoproliferative syndrome manifesting as chronic symmetrical sclerosing dacryo-sialadenitis with subsequent secondary portal hypertension and remarkable IgG4-linked IL-4 elevation. Rheumatology. 49: pp.1789-1791, 2010.
  3. Suzuki K, Kameda H, Amano K, Nagasawa H, Takeii H, Nishi E, Okuyama A, Tsuzaka K, and Takeuchi T. Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus. Rheumatology Int. on line, 2010 Feb 18.
  4. Nagasawa H, Kameda H, Sekiguchi N, Amano K, and Takeuchi T. Normalization of physical function by infliximab in RA patients: Factors associated with normal physical function. Clin Exp Rheum. 28:pp.365-372, 2010.
  5. Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, Nojima T, Miyasaka N, and Koike T. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis, RRR (remission induction by Remicade in RA) study. Ann Rheum Dis. 69:pp.1286-1291, 2010.
  6. Nagasawa H, Kameda H, Sekiguchi N, Amano K, and Takeuchi T. Differences between the Health Assessment Questionnaire Disability Index (HAQ-DI) and the modified HAQ (mHAQ) score before and after infliximab treatment in patients with rheumatoid arthritis. Modern Rheum. 20:pp.337-342, 2010.
  7. Kameda H, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, Tsukano M, Kasama T, Shiozawa S, Tanaka Y, Takeuchi T; Japan Biological Agent Study Integrated Consortium (JBASIC). Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: A randomized trial. Mod Rheumatol 20: pp.531-538, 2010.
  8. Tsuzaka K, Itami Y, Takeuchi T, Shinozaki N, and Morishita T. ADAMTS5 is a biomarker for prediction of the response to Infliximab in patients with rheumatoid arthritis. J Rheum. 37:pp.1454-1460, 2010.
  9. Takeuchi T and Kameda H. The Japanese experiences with biologic therapies for Rheumatoid Arthritis. Nature Rev Rheum. 6:pp.644-652, 2010.
  10. Yamanaka H, Tanaka Y, Inoue E, Hoshi D, Momohara S, Hanami K, Yunoue N, Saito K, Amano K, Kameda H, Takeuchi T. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol. 21: pp.122-133, 2011.
  11. Okuyama A, Nagasawa H, Suzuki K, Kameda H, Kondo H, Amano K, and Takeuchi T. Fc gamma receptor IIIb polymorphism and usage of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis. 70:pp.299-304, 2011.
  12. Takeuchi T, Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T, and Koike T. Baseline tumor necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 70:pp.1208-1215, 2011.
  13. Yoshimoto K, Setoyama Y, Tsuzaka K, Abe T, and Takeuchi T. Reduced expression of TCR zeta is involved in the abnormal production of cytokines by peripheral T cells of patients with systemic lupus erythematosus. J Biomed Biotechnol. 2010;pii: 509021. Epub 2010 Sep 6.
  14. Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, Tsukano M, Kasama T, Shiozawa S, Tanaka Y, Yamanaka H, and Takeuchi T. Continuation of Methotrexate resulted in better clinical and radiographic outcomes than its discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study. J Rheumatol. In press.
  15. Kaneko Y, Kuwana M, Kameda H, and Takeuchi T. Sensitivity and Specificity of 2010 rheumatoid arthritis classification criteria. Rheumatology. In press.
  16. Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasana N, and , Harigai M. Incidence and risk factors for serious infection in rheumatoid arthritis patients treated with tumor necrosis factor (TNF) inhibitors: a report from the registry of Japanese Rheumatoid Arthritis Patients for Long-Term Safety. J Rheumatol. In press.
  17. Suzuki K, Setoyama Y, Yoshimoto K, Tsuzaka K, Abe T, and Takeuchi T. Decreased mRNA expression of two Foxp3 isoforms in peripheral blood mononuclear cells from patients with rheumatoid arthritis and systemic lupus erythematosus. Int J Immunopathol and Pharmacology. 24:pp.7-14, 2011.
  18. Hashimoto J, Garnero P, van der Heijde, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Yoshikawa H, and Nishimoto N. Humanized anti-interleukin 6 receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomakers, radiography, and BMI: data from the SAMURAI study. Modern Rheum. 21:pp.10-15, 2011.
  19. Takeuchi T, Tanaka Y, Amano K, Hoshi D, Nawata M, Nagasawa H, Satoh E, Saitao K, Kaneko Y, Fukuyo S, Kurasawa T,Hanami K, Kameda H, and Yamanaka H. Clinical, radiographic, and functional effectiveness of tocilizumab for rheumatoid arthritis patients -REACTION 52-week study. Rheumatology. In press.
  20. Takeuchi T. Revolutionary change in rheumatoid arthritis management with biological therapy. Keio J Med. In press.
  21. Kameda H, Tokuda H, Sakai F, Johkoh T, Mori S, Yoshida Y, Takayanagi N, Taki H, Hasegawa Y, Hatta K, Yamanaka H, Dohi M, Hashimoto S, Yamada H, Kawai S, Takeuchi T, Tateda K, Goto H. Clinical and radiological features of acute-onset interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents: Importance of Pneumocystis pneumonia in Japan revealed by a multicenter study. Intern Med. 50:pp.305-313, 2011.
  22. Koreeda Y, Higashimoto I, Yamamoto M, Takahashi M, Kaji K, Fujimoto M, Kuwana M, and Fukuda Y. Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. Intern Med. 49: pp.361-369, 2010.
  23. Kuwana M. Sensorineural hearing loss as a common manifestation in patients with mixed connective tissue disease. Int J Clin Rheumatol. 5: pp.165-167, 2010.
  24. Yamaguchi Y, Takahashi H, Satoh T, Okazaki Y, Mizuki N, Takahashi K, Ikezawa Z, and Kuwana M. Natural killer cells control a T helper 1 response in patients with Behçet’s disease. Arthritis Res Ther. 12: pp.R80, 2010.
  25. Seta N and Kuwana M. Derivation of multipotent progenitors from human circulating CD14+ monocytes. Exp Hematol. 38: pp.557-563, 2010.
  26. Furuya Y, Satoh T, and Kuwana M. Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension. Int J Rheumatol. 2010: pp.720305, 2010.
  27. Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, Masuda I, Tochimoto A, Baba S, Okamoto Y, Ota Y, and Yamanaka H. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology. 49: pp.1713-1719, 2010.
  28. Sato S, and Kuwana M. Clinically amyopathic dermatomyositis. Curr Opinion Rheumatol. 22: pp.639-643, 2010.
  29. Furuya Y, Okazaki Y, Kaji K, Sato S, Takehara K, and Kuwana M. Mobilization of endothelial progenitor cells by intravenous cyclophosphamide in patients with systemic sclerosis: potential association with efficacy for interstitial lung disease. Rheumatology. 49: pp.2375-2380, 2010.
  30. Yamaguchi Y, Okazaki Y, Seta N, Satoh T, Takahashi K, Ikezawa Z, and Kuwana M. Enhanced angiogenic potency of monocytic endothelial progenitor cells in patients with systemic sclerosis. Arthritis Res Ther. 12: p.R205, 2010.
  31. Suzuki S, Utsugisawa K, Nagae Y, Satoh T, Kuwana M, and Suzuki N. Clinical and immunological differences between early and late-onset myasthenia gravis in Japan. J Neuroimmunol. 230: pp.148-152, 2011.
  32. Gono T, Kawaguchi Y, Ozeki E, Ota Y, Satoh T, Kuwana M, Hara M, and Yamanaka H. Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis. Mod Rheumatol. 21: pp.223-227, 2011.
  33. Kurata Y, Fujimura K, Kuwana M, Tomiyama Y, and Murata M. Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review. Int J Hematol. 93: pp.329-335, 2011.
  34. Kobayashi I, Okura Y, Yamada M, Kawamura N, Kuwana M, and Ariga T. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr. 158: pp.675-677, 2011.
  35. Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, Komura K, Nakamura M, Kodera M, Suga M, Higashi A, Ogusu K, Tsutusi K, Furusaki A, Tanabe H, Sasaoka S, Muro Y, Yoshikawa M, Ishiguro N, Ayano M, Muroi E, Fujikawa K, Umeda Y, Kawase M, Mabuchi E, Asano Y, Sodemoto K, Seishima M, Yamada H, Sato S, Takehara K, and Fujimoto M. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multi-centre, cross-sectional study. Arch Dermatol. 147: pp.391-398, 2011.
  36. Noda S, Asano Y, Tamaki Z, Hirabayashi M, Yamamoto M, Takekoshi T, Hoashi T, Sugaya M, Morimoto R, Eto T, Kaji K, Fujimoto M, Kuwana M, and Sato S. Dermatomyositis with anti-OJ antibody. Rheumatol Int. In press.
  37. Hara S, Henmi T, Kawakami A, Fujikawa K, Mukae H, Ishimatsu Y, Sakamoto N, Kakugawa T, Kaji K, Fujimoto M, Kuwana M, Tsukada T, Satoh K, Motomura M, Tamai M, Nakamura H, Ida H, Hayashi T, Origuchi T, Eguchi K, and Kohno S. Clinical, serologic and magnetic resonance imaging of 3 cases of inflammatory myopathy with abundant macrophages in the Japanese population. Rheumatol Int. In press.
  38. Yamaguchi Y, Yasuoka H, Stolz DB, Feghali-Bostwick CA. Decreased caveolin-1 levels contribute to fibrois and deposition of extracellular IGFBP-5. J Cell Mol Med. In press.

2009年

  1. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, and Kishimoto T. Study of Active controlled Tocilizumab monotherapy for Rheumatoid Arthritis Patients with an Inadequate Response to Methotrexate (SATORI):significantly reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheum 19:12-19, 2009.
  2. Suzuki K, Nagasawa H, Kameda H, Amano K, Kondo T, Itoyama S, Tanaka Y, Takeuchi T. Severe acute thrombotic exacerbation in two cases with anti-phospholipid syndrome after retreatment with rituximab in phase I/II clinical trial for refractory systemic lupus erythematosus. Rheumatology 48:198-199, 2009.
  3. Suzuki K, Kameda H, Amano K, Nagasawa H, Sekiguchi H, Nishi E, Ogawa H, Tsuzaka K, and Takeuchi T. Single Center Prospective Study for Efficacy and Safety of Tacrolimus in Rheumatoid Arthritis. Rheumatology Int 29:431-6, 2009.
  4. Nagasawa H, Kameda H, Sekiguchi N, Amano K, and Takeuchi T. Improvement of the HAQ score by infliximab treatment in patients with RA: its association with disease activity and joint destruction. Mod Rheum 19: 166-172, 2009.
  5. Komano Y, Harigai M, Koike R, Sugiyama H, Ogawa J, Saito K, Sekiguchi N, Inoo M, Onishi I, Ohashi H, Amamoto F, Miyata M, Kageyama G, Imaizumi K, Tokuda H, Okochi Y, Tanaka Y, Takeuchi T, and Miyasaka N. Pneumocystis pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis & Rheum 61:305-12, 2009.
  6. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, and Azuma J. Long-term safety and efficacy of tocilizumab, an anti-interleukin(IL)-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 68: 1580-84, 2009.
  7. Sawada T, Inokuma S, Sato T, Ohtsuka T, Saeki Y, Takeuchi T, Matsuda T, Takemura T, and Sagawa A. Leflunomide-induced interstitial lung disease: Prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology 48:1069-72, 2009.
  8. Takeuchi T, Miyasaka N, Inoue K, Abe T, and Koike T. The Impact on Radiographic and Clinical Response of Infliximab Therapy Concomitant with Methotrexate in Patients with Rheumatoid Arthritis by the Trough Serum Level in the Dose Escalating Study: the RISING Study. Mod Rheumatology 19:478-87, 2009.
  9. Hashimoto J, Garnero P, van der Heijde, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T , Yoshikawa H, and Nishimoto N. A combination of biochemical markers of cartilages and markers of cartilage and bone turnover, radiographic image and body mass index to predict progression of joint destruction in patients with rheumatoid Arthritis treated with Disease modifying Anti-Rheumatic Drugs. Mod Rheum 19: 273-282, 2009.
  10. Tanino M, Matoba R, Nakamura S, Kameda H, Amano K, Okayama T, Nagasawa H, Suzuki K, Matsubara K, and Takeuchi T. Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells. Biochem Biophys Research Comm 387: 261-265, 2009.
  11. Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Fujii K, Freundlich B, and Suzukawa M. Post-marketing surveillance of the safety and efficacy of etanercept in Japan. J Rheum 36:898-906, 2009.
  12. Sato T, Inokuma S, Sagawa A, Matsuda T, Takemura T, Ohtsuka T, Saeki Y, Takeuchi T, and Sawada T. Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis. Rhematology 48:1265-8, 2009.
  13. Ogawa H, Kameda H, Amano K, and Takeuchi, T. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus 19:162-169, 2010.
  14. Suzuki K, Tamaru J, Okuyama A, Kameda H, Amano K, Nagasawa H, Nishi, E, Yoshimoto K, Setoyama Y, Kaneko K, Osada H,Honda N, Yasaki Y, Itoyama S, Tsuzaka K, and Takeuchi T. IgG4-positive multi-organ lymphoproliferative syndrome manifesting as chronic symmetrical sclerosing dacryo-sialo-adenitis with subsequent secondary portal hypertension and remarkable IgG4-linked IL-4 elevation. Rheumatology, in press.
  15. Suzuki K, Kameda H, Amano K, Nagasawa H, Takeii H, Nishi E, Okuyama A, Tsuzaka K, and Takeuchi T. Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus. Rheumatolog 29:431-436, 2009.
  16. Kameda H, Amano K, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Suzuki K,Takeuchi T. Notable difference between the development of vertebral fracture and osteonecrosis of the femoral head in patients treated with high-dose glucocorticoids for systemic rheumatic diseases. Intern Med. 48(22): 1931-8, 2009.
  17. Tsuzaka K, Itami Y, Takeuchi T, Shinozaki N, Morishita T. ADAMTS5 is a biomarker for prediction of the response to Infliximab in patients with rheumatoid arthritis. J Rheumatol 37:1454-1560, 2010.
  18. Nagasawa H, Kameda H, Sekiguchi N, Amano K, and Takeuchi T. Normalization of physical function by infliximab in RA patients: Factors associated with normal physical function. Clin Exp Rheum 28:365-72, 2010.
  19. Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, Nojima T, Miyasaka N, and Koike T. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis, RRR (remission induction by remicade in RA) study. Ann Rheum Dis 69:1286-91, 2010.
  20. Nagasawa H, Kameda H, Sekiguchi N, Amano K, and Takeuchi T. Differences between the Health Assessment Questionnaire Disability Index (HAQ-DI) and the modified HAQ (mHAQ) score before and after infliximab treatment in patients with rheumatoid arthritis. Mod Rheum, in press.
  21. Kameda H, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, Tsukano M, Kasama T, Shiozawa S, Tanaka Y, Takeuchi T, and Japan Biological Agent Integrated Consortium (J-BASIC). The comparison of efficacy and safety between continuation and discontinuation of methotrexate (MTX) at the commencement of etanercept in patients with active rheumatoid arthritis despite MTX therapy: 24-week results from the JESMR study. Modern Rheumatology, in press.
  22. Yamanaka H, Tanaka Y, Hoshi D, Inoue E, Saito K, Amano K, Kameda H, and Takeuchi T. Efficacy of tocilizumab for rheumatoid arthritis patients in daily practice in Japan –message from REACTION study, in press.
  23. Keiko Yoshimoto, Yumiko Setoyama, Kensei Tsuzaka, Tohru Abe, Tsutomu Takeuchi: Reduced expression of TCR zeta is involved in the abnormal production of cytokines by peripheral T Cells of patients with systemic lupus erythematosus.Journal of Biomedicine and Biotechnology (submitted)
  24. Satoh T, Pandey JP, Okazaki Y, Asahi A, Kawakami Y, Ikeda Y, and Kuwana M. Single nucleotide polymorphism of interleukin-1β associated with Helicobacter pylori infection in immune thrombocytopenic purpura. Tissue Antigens. 73(4): 353-357, 2009.
  25. Takada T, Hirakata M, Suwa A, Kaneko Y, Kuwana M, Ishihara T, Ikeda Y. Clinical and histopathological features of myopathies in Japanese patients with anti-SRP autoantibodies. Mod. Rheumatol. 19(2): 156-164, 2009.
  26. Kawaguchi Y, Nakamura Y, Matsumoto I, Nishimaki E, Satoh T, Kuwana M, Sumida T, and Hara M. Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis: contribution to severe gastrointestinal tract dysmotility. Ann. Rheum. Dis. 68(5): 710-714, 2009.
  27. Nagata E, Hattori H, Kato M, Ogasawara S, Suzuki S, Shibata M, Shimizu T, Hamada J, Osada T, Takaoka R, Kuwana M, Tsunoda T, Aiso S, Takizawa S, Suzuki N, and Takagi S. Identification of biomarkers associated with migraine with aura. Neurosci. Res. 64(1): 104-110, 2009.
  28. Fujikawa K, Kawakami A, Kaji K, Fujimoto M, Kawashiri S, Iwamoto N, Aramaki T, Ichinose K, Tamai M, Kamachi M, Nakamura H, Ida H, Origuchi T, Ishimoto H, Mukae H, Kuwana M, Kohno S, Takehara K, Sato S, and Eguchi K. Association of distinctive clinical subsets with myositis-specific autoantibodies toward anti-155/140kD polypeptides, anti-140kD polypeptides, and anti-aminoacyl tRNA synthetases in patients with dermatomyositis of Japanese population: a single-center, cross-sectional study. Scand. J. Rheumatol. 38(4): 263-267, 2009.
  29. Arnold DM, Bernotas A, Nazi I, Stasi R, Kuwana M, Liu Y, Kelton JG, and Crowther M. Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review. Haematologica. 94(6): 850-856, 2009.
  30. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, and Kuwana M. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 60(7): 2193-2200, 2009.
  31. Fertig N, Domsic RT, Rodriguez-Reyna T, Kuwana M, Lucus M, Medsger TA Jr, and Feghali-Bostwick CA. Anti-U11/U12 RNP antibodies in systemic sclerosis: A new serologic marker associated with pulmonary fibrosis. Arthritis Rheum. 61(7): 958-965, 2009.
  32. Matsuyama T, Kuwana M, Matsumoto M, Isonishi A, Inokuma S, and Fujimura Y. Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases. Thromb. Haemost. 102(2): 371-378, 2009.
  33. Yoshida H, Ishida H, Yoshihara T, Oyamada T, Kuwana M, Imamura T, and Morimoto A. Complication of Evans’ syndrome in an infant with hereditary spherocytosis: a case report. J. Hematol. Oncol. 2: 40, 2009.
  34. Kuwana M, Okazaki Y, and Kaburaki J. Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis. Mod. Rheumatol. 19(5): 530-535, 2009.
  35. Suzuki S, Utsugisawa K, Yoshikawa H, Motomura M, Matsubara S, Yokoyama K, Nagane Y, Maruta T, Satoh T, Sato H, Kuwana M, and Suzuki N. Autoimmune targets to heart and skeletal muscles in myasthenia gravis. Arch. Neurol. 66(11): 1334-1338, 2009.
  36. Kawaguchi Y, Ota Y, Kawamoto M, Ito I, Tsuchiya N, Sugiura T, Katsumata Y, Soejima M, Sato S, Hasegawa M, Fujimoto M, Takehara K, Kuwana M, Yamanaka H, and Hara M. Association study of a polymorphism of the CTGF gene and susceptibility to systemic sclerosis in the Japanese population. Ann. Rheum. Dis. 2009; 68(12): 1921-1924.
  37. Seta N, Kobayashi S, Hashimoto H, and Kuwana M. Characterization of autoreactive T-cell clones to myeloperoxidase in patients with microscopic polyangiitis and healthy individuals. Clin. Exp. Rheumatol. 27(5): 826-829, 2009.
  38. Satoh T, Ishikawa O, Ihn H, Endo H, Kawaguchi Y, Sasaki T, Goto D, Takahashi K, Takahashi H, Misaki Y, Mimori T, Muro Y, Yazawa N, Sato S, Takehara K, and Kuwana M. Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay. Rheumatology. 48(12): 1570-1574, 2009.
  39. Kaneko Y, Suwa A, Hirakata M, Ikeda Y, and Kuwana M. Clinical associations with autoantibody reactivities to individual components of U1 small nuclear ribonucleoprotein. Lupus. 19(3): 307-312, 2010.
  40. Koreeda Y, Higashimoto I, Yamamoto M, Takahashi M, Kaji K, Fujimoto M, Kuwana M, and, Fukuda Y. Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. Intern. Med. 49(5): 361-369, 2010.
  41. Kuwana M. Sensorineural hearing loss as a common manifestation in patients with mixed connective tissue disease. Int. J. Clin. Rheumatol. 5(2): 165-167, 2010.
  42. Suwa A, Hirakata M, Kaneko Y, Sato S, Suzuki Y, Kuwana M. Successful treatment of refractory polymyositis with the immunosuppressant mizoribine: case report. Clin Rheumatol. 28(2):227-229, 2009.
  43. Yamaguchi Y, Takahashi H, Satoh T, Okazaki Y, Mizuki N, Takahashi K, Ikezawa Z, and Kuwana M. Natural killer cells control a T helper 1 response in patients with Behçet’s disease. Arthritis Res. Ther. In press.
  44. Seta N and Kuwana M. Derivation of multipotent progenitors from human circulating CD14+ monocytes. Exp. Hematol. In press.
  45. Kuwana M, Okazaki Y, and Ikeda Y. Splenic macrophages maintain the anti-platelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura. J. Thromb. Haemost. 7(2): 322-329, 2009.
  46. Hironari Hanaoka, Yuka Okazaki, Takashi Satoh, Yuko Kaneko, Hidekata Yasuoka, Noriyuki Seta and Masataka Kuwana.Emergence of anti-double strand DNA (dsDNA) antibody-secreting cells into peripheral blood predicts disease flare in patients with systemic lupus erythematosus(SLE). Arthritis Rheum, 60:S340, 2009.
  47. Furuya Y, Okazaki Y, Kaji K, Sato S, Takehara K, and Kuwana M. Mobilization of endothelial progenitor cells by intravenous cyclophosphamide in patients with systemic sclerosis: potential association with efficacy for interstitial lung disease. Rheumatology. In revision.
  48. Tokuhira M, Hanzawa K, Watanabe R, Sekiguchi Y, Nemoto T, Toyozumi Y, Tamaru-J-I, Itiyama S, Suzuki K, Kameda H, Mori S, Kizaki M. Co-existence of acute myeloid leukemia with multilineage dysplasia and Epstein-Barr virus-associated T-cell lymphoproliferative disorder in a patient with rheumatoid arthritis. J Hematol Oncol 2:27,2009.
  49. Yamaguchi Y, Okazaki Y, Seta N, Satoh T, Takahashi K, Ikezawa Z, and Kuwana M. Enhanced angiogenic potency of monocytic endothelial progenitor cells in patients with systemic sclerosis. J. Invest. Dermatol. Submitted for publication.
  50. Sato H, Yanagimachi E, Arai H, Okazaki Y, and Kuwana M. Mycobacterium avium infection of the lung complicated by chronic immune thrombocytopenic purpura. Chest. Submitted for publication.
  51. Yasuoka H, Yamaguchi Y, Feghali-Bostwick CA. The pro-fibrotic factor IGFBP-5 induces lung fibroblast and mononuclear cell migration. Am J Respir Cell Mol Biol, 41:179-88, 2009.
  52. Yasuoka H, Hsu E, Ruiz X, Steinman RA, Choi AMK, Feghali-Bostwick CA. The fibrotic phenotype induced by IGFBP-5 is regulated by MAPK activation and Egr-1-dependent and –independent mechanisms. Am J Pathol, 175:605-15. 2009.
  53. Veraldi KL, Gibson BT, Yasuoka H, Myerburg MM, Kelly EA, Balzar S, Jarjour NN, Pilewski JM, Wenzel SE, Feghali-Bostwick CA. Role of Insulin-like Growth Factor Binding Protein-3 in Allergic Airway Remodeling. Am J Respir Crit Care Med. 180:611-7, 2009.